January 29, 2009 article Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab Blood DOI: 10.1182/blood-2008-11-189944 OpenAlex Authors 0 Author list not loaded yet. Cited by 21 stored of 362 Search Sort Most cited Newest Oldest Patent citations Title Any typearticle review book-chapter conference-paper preprint dissertation book dataset other Any fieldAgricultural and Biological Sciences Arts and Humanities Biochemistry, Genetics and Molecular Biology Business, Management and Accounting Chemical Engineering Chemistry Computer Science Decision Sciences Dentistry Earth and Planetary Sciences Economics, Econometrics and Finance Energy Engineering Environmental Science Health Professions Immunology and Microbiology Materials Science Mathematics Medicine Neuroscience Nursing Pharmacology, Toxicology and Pharmaceutics Physics and Astronomy Psychology Social Sciences Veterinary Open access Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti‐C5 therapy 2026 HemaSphere article Immunology and Microbiology Complement system in diseases Open access 0 citations Insights in bone marrow failure syndromes: take home messages from the 3rd ESH-EBMT-EHA-IPIG translational research conference 2025 Bone Marrow Transplantation article Biochemistry, Genetics and Molecular Biology Blood disorders and treatments Open access 1 citations Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors 2025 The Lancet Haematology article Immunology and Microbiology Complement system in diseases Open access 15 citations Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH 2024 Blood article Immunology and Microbiology Complement system in diseases Open access 27 citations The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms 2024 Drug Discovery Today article Immunology and Microbiology Complement system in diseases Open access cited by 1 patent 24 citations Efficacy, Safety, and Quality of Life of Pegcetacoplan in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria Treated within the Phase 3 PEGASUS Trial 2024 Acta Haematologica article Immunology and Microbiology Complement system in diseases Open access 4 citations Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria 2024 Blood Advances article Immunology and Microbiology Complement system in diseases Open access 18 citations Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH 2024 Blood Advances article Immunology and Microbiology Complement system in diseases Open access 34 citations Fatigue and health‐related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data 2023 European Journal Of Haematology article Immunology and Microbiology Complement system in diseases Open access 6 citations Paroxysmal nocturnal hemoglobinuria: Where we stand 2023 American Journal of Hematology article Immunology and Microbiology Complement system in diseases Open access 24 citations The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective 2022 Hematology article Immunology and Microbiology Complement system in diseases Open access 12 citations The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target 2022 Immunological Reviews review Immunology and Microbiology Complement system in diseases Open access 52 citations Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial 2022 The Lancet Haematology article Immunology and Microbiology Complement system in diseases Open access 74 citations The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient‐reported insights on symptoms and quality of life 2022 European Journal Of Haematology article Immunology and Microbiology Complement system in diseases Open access 38 citations Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria 2022 Expert Opinion on Emerging Drugs article Immunology and Microbiology Complement system in diseases 7 citations Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress 2022 Seminars in Hematology article Immunology and Microbiology Complement system in diseases Open access 20 citations Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls 2022 Seminars in Immunology article Immunology and Microbiology Complement system in diseases 18 citations How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future 2021 British Journal of Haematology article Immunology and Microbiology Complement system in diseases Open access 74 citations Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study 2021 Bone Marrow Transplantation article Immunology and Microbiology Complement system in diseases 60 citations Halting targeted and collateral damage to red blood cells by the complement system 2021 Seminars in Immunopathology article Immunology and Microbiology Complement system in diseases Open access 20 citations 1–20 of 21 Page 1 / 2 Next → References 0